Is NCT06855160 recruiting in Huntington Park, CA?

Yes, NCT06855160 is currently recruiting participants at its Huntington Park, CA location. This chickenpox clinical trial is actively enrolling qualified participants.

How do I join the chickenpox clinical trial in Huntington Park?

To join this clinical trial in Huntington Park, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Huntington Park clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Chickenpox Clinical Trial in Huntington Park, CA

About This Chickenpox Study in Huntington Park

This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection. It compares the GSK vaccines to Merck's chickenpox vaccine, administered just under the skin. Additionally, the study will evaluate the immune response and safety of giving the GSK vaccines along with other childhood vaccines through a muscle injection.

Sponsor: GlaxoSmithKline

Who Can Participate

Inclusion Criteria

Participant's parent(s)/ Legally acceptable representatives (LAR\[s\]), who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the eDiaries, return for follow-up visits).

Written or witnessed/thumb printed informed consent obtained from the participant's parent(s)/LAR(s) prior to performance of any study-specific procedure.

Healthy participants as established by medical history and clinical examination before entering into the study.

A male or female between, and including, 12 to 15 months of age (i.e., from the day of 1-year birthday until the day before 16 months of age) at the time of the administration of study interventions.

Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions:

Participant who previously received the primary series of PCV in the first year of life with last dose at least 60 days prior to the administration of study intervention.

Exclusion Criteria

History of any reaction or hypersensitivity likely to be exacerbated by any component of the study interventions including hypersensitivity to neomycin or gelatin.

Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).

Hypersensitivity to latex.

Major congenital defects, as assessed by the investigator.

Recurrent history of uncontrolled neurological disorders or seizures.

History of measles, mumps, rubella, or varicella disease.

Active untreated tuberculosis.

Participants with bleeding disorders (e.g., thrombocytopenia or any coagulation disorder).

Condition that in the judgment of the investigator would make intramuscular injection unsafe.

Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study. Prior/Concomitant therapy

Use of any investigational or non-registered product (drug, vaccine or invasive medical device) other than the study interventions during the period beginning 30 days before the dose of study interventions administration (Day -29 to Day 1), or their planned use during the study period.

Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune modifying treatments at any time up to the end of the study. \- Up to 90 days prior to the study intervention administration:

For corticosteroids, this will mean prednisone equivalent \>=0.5 mg/kg/day with maximum of 20 mg/day for pediatric participants. Inhaled and topical steroids are allowed.

Administration of immunoglobulins and/or any blood products or plasma derivatives. \- Up to 180 days prior to study interventions administration: long acting immune-modifying drugs including among others immunotherapy (e.g., tumor necrosis factor-inhibitors), monoclonal antibodies (except the ones not interfering with the immune response to the study vaccines, e.g., nirsevimab), antitumoral medication.

Previous vaccination against measles, mumps, and rubella.

Previous vaccination against varicella virus.

Previous vaccination against hepatitis A virus.

Only for children in countries where PCV is recommended at 12 to 15 months of age as per national immunization schedule and provided as part of the study interventions, participant who previously received a booster dose of any PCV. Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). Other exclusion criteria

Any study personnel or their immediate dependents, family, or household members.

Child in care.

Participants with the following high-risk individuals in their household: • Immunocompromised individuals.

Pregnant women without documented history of varicella.

Newborn infants of mothers without documented history of varicella.

Newborn infants born \<28 weeks of gestation

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntington Park?

Yes, this clinical trial (NCT06855160) has an active research site in Huntington Park, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chickenpox Treatment Options in Huntington Park, CA

If you're searching for chickenpox treatment options in Huntington Park, CA, this clinical trial (NCT06855160) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntington Park research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced chickenpox specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chickenpox clinical trials near you to find additional studies recruiting in your area.

Chickenpox Clinical Trial in Huntington Park, CA

Expert Care in Huntington Park

IRB Approved

No-Cost Care

Apply for This Huntington Park Location

Why Participate?

Simple Process